Vicissitudes of Preventive Medicine and a New Challenge

Summary

Objectives: Significant changes in mortality patterns are part of the changing population demographics. This paper explores their implications for health evaluation and screening programs.

Methods: A review of selected age-adjusted mortality rates from the National Vital Statistics Reports of the USA was undertaken and their change over the last five decades analyzed.

Results: The review shows a continued decline in mortality rates from leading causes of death, such as heart disease, cancer, stroke, pneumonia and influenza, and a sharp rise in the death rates from Alzheimer’s disease. Available means for detection of Alzeimer’s disease are summarized.

Conclusion: Given the emerging possibilities for the treatment and prevention of the progression of Alzheimer’s disease, tests for early detection of Alzheimer’s should be included in health screening examinations.

Keywords

Preventive medicine - vital statistics - dementia - Alzheimer’s disease

• References

• 1 Centers for Disease Control and Prevention, National Center for Health Statistics US.. Department of Health and Human Services. Births and Deaths: Preliminary data for 1998. National Vital Statistics Reports 1999; 47 (Suppl. 25) 471-5.
• 2 Centers for Disease Control and Prevention, National Center for Health Statistics US.. Department of Health and Human Services. Deaths: Final Data for 1997. National Vital Statistics Reports 1999; 47 (Suppl. 19) 1-104.
• 3 Centers for Disease Control and Prevention, National Center for Health Statistics US.. Department of Health and Human Services. Mortality from Alzheimer’s disease:An update. National Vital Statistics Reports 1999; 47: 1-5.
• 4 Centers for Disease Control and Prevention, National Center for Health Statistics US.. Department of Health and Human Services. United States Life Tables, 1997. National Vital Statistics Reports 1999; 47: 1-33.
• 5 Nusseder W, Mackenback J. Lack of improvement of life expectancy at advanced ages in the Netherlands. Internatnl J Epidemiol 2000; 29: 140-8.
• 6 Report of the U.S.. Preventive Services Task Force. Screening for Dementia. In: Guide to Clinical Preventive Services. 2 ed; 1996. p. 531-40.
• 7 Cummings J, Khachaturian Z. Definitions and diagnostic criteria. In: Clinical Diagnosis and Management of Alzheimer’s Disease. Boston: Butterworth-Heinemann; 1996
• 8 Recognition and Initial Assessment of Alzheimer’s Disease and Related Dementias.. Clinical Practice Guideline No. 19. Rockville, MD: Agency for Health Care & Policy Research, US DHHS, AHCPR; Pub No. 97-0702; 1996. November.
• 9 Fratiglioni L, DeRonchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs & Aging 1999; 5: 365-75.
• 10 Anderson K, Launer L, Dewey M. et al. gender differences in the incidence of AD and vascular dementia:The EURODEM Studies. Neurology 2000; 53: 1992-7.
• 11 Gao S, Hendrie H, Hall K, Hui S. The relationship between age, sex, and the incidence of dementia and Alzheimer’s disease. Arch Gen Psychiatry 1998; 55: 809-15.
• 12 Berteler M, Ott A, Hofman A. The new epidemic: Frequency of dementia in the Rotterdam study. Haemostasis 1998; 28: 117-23.
• 13 Lobo A, Launer L, Frataglioni L. et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology 2000; 54 Suppl 5 S4-S9.
• 14 Gangula M, Dodge H, Chen P. et al. Ten-year incidence of dementia in a rural elderly U.S. community population: The MOVIES Project. Neurology 2000; 54: 1109-16.
• 15 Rocca W, Cha R, Waring S, Kokmen E. Incidence of dementia and Alzheimer’s disease: An analysis from Rochester, Minnesota, 1975-1984. Am J Epidemiol 1998; 148: 51-62.
• 16 Elias M, Beiser A, Wolf P. et al. The preclinical phase of Alzheimer’s disease; A 22-year prospective study of the Framingham cohort. Arch Neurol 2000; 57: 808-13.
• 17 Jorm A, Jolley D. The incidence of dementia: A meta-analysis. Neurology 1998; 51: 728-33.
• 18 Thomassen R, van Schaick H, Blansjaar B. Prevalence of dementia over age 100. Neurology 1998; 50: 283-6.
• 19 Aguero-Torres H, Frataglioni L, Guo Z. et al. Mortality from dementia in advanced age: A 5-year follow-up study of incident dementia cases. J Clin Epidmiol 1999; 52 (Suppl. 08) 737-43.
• 20 Liu H, Fuh J, Wang S. et al. Prevalence and subtypes of dementia in a rural Chinese population. Alzheimer’s Dis & Assoc Disorders 1998; 12: 127-34.
• 21 O’Hara R, Mumenthaler M, Yesavage J. Update on Alzheimer’s disease: Recent findings and treatments. West J Med 2000; 172: 115-20.
• 22 Rocca W. Dementia, Parkinson’s disease, and stroke in Europe: A commentary. Neurology 2000; 54 Suppl 5 S38-S40.
• 23 Daly E, Zaitchik D, Copeland M. et al. Predicting conversion to Alzheimer’s disease using standardized clinical information. Arch Neurol 2000; 57: 675-44.
• 24 Office of Disease Prevention and Health Promotion, Public Health Service, Services US Department of Health and Human Services.. Cognitive and Functional Impairment. In: Clinician’s Handbook of Preventive Services. Put Prevention into Practice. Washington, DC: US Govt Print Office; 1994
• 25 Office of Disease Prevention and Health Promotion, US Department of Health and Human Services.. Clinical preventive services for normal-risk adults. Prevention Report 1998; 13: 12.
• 26 Canadian Task Force in the Periodic Health Examination.. Canadian Guide to Preventive Health Care. Ottawa: Canadian Communication Group; 1994
• 27 Fletcher A. Multidimensional assessment of elderly people in the community. Brit Med Bull 1998; 54: 945-60.
• 28 Froelich T, Robison J, Inouye S. Screening for dementia in the outpatient setting: The time and change test. J Am Geriatr Soc 1998; 46: 1506-11.
• 29 Katzman R, Brown T, Fuld P. et al. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 1983; 140: 734-9.
• 30 Folstein M, Folstein S, McHugh P. “Mini-Mental State”: A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 25: 189-98.
• 31 McDowell I, Kristjanssen B, Hill G, Hebert R. Community screening for dementia: The Mini-Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. J Clin Epidmiol 1997; 50: 377-83.
• 32 Hogan D, Ebly E. Predicting who will develop dementia in a cohort of Canadian survivors. Can J Neurol Sc. 2000; 27: 18-24.
• 33 Small B, Frataglioni L, Vitanen M. et al. The course of cognitive impairment in pre-clinical Alzheimer’s disease; three and six year followup of a population-based sample. Arch Neurol 2000; 57: 839-44.
• 34 Sahadevan S, Lim P, Li Tan N, Chan S. Diagnostic performance of two mental status tests in the older Chinese: Influence of education and age in cut-off values. Int J Geriat Psychiatry 2000; 15: 234-41.
• 35 Zhang M, Katzman R, Salmon D. et al. The prevalence of dementia and Alzheimer’s disease in Shanghai, China: Impact of age, gender, and education. Ann Neurology 1990; 27: 428-37.
• 36 Tariot P, Solomon P, Morris J. et al. A 5-month randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-76.
• 37 Raskind M, Peskind E, Wessel T. et al. Galanta-mine in AD. Neurology 2000; 54: 2261-8.
• 38 Patterson C. Detecting cognitive impairment in the elderly. In: Preventing Disease: Beyond the Rhetoric. New York: Springer-Verlag; 1990
• 39 Warner J, Butler R. Alzheimer’s Disease. Clinical Evidence. London: BMJ Pub Group; 2000